ALCIDION GROUP LIMITED — Board/Management Information 2021

Jun 29, 2021

==> picture [166 x 43] intentionally omitted <==

30 June 2021

Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

Resignation of Non-Executive Director

Melbourne, Australia – Alcidion Group Limited (ASX:ALC) advises that its Board has today announced the resignation of Ray Blight as Non-Executive Director, effective 30 June 2021.

This announcement coincides with the conclusion of Mr. Blight’s contracting agreement, which commenced on 1 September 2019 following his retirement as Executive Chair of Alcidion. Mr. Blight was due for re-election at the Company’s next AGM in November on rotation.

As part of Alcidion’s Board renewal and succession planning process, in the six months leading up to the Annual General Meeting, the Company evaluates its Board composition, performance, and skills ahead of the nomination of Directors due for re-election. This is a Board-led initiative that supports an active and measured process to ensure the Board reflects the current and future needs of Alcidion as the Company continues its path of accelerated growth.

Alcidion is well advanced in the identification of suitable independent Non-Executive Director candidates to replace Mr. Blight and expects to announce a replacement in the near term.

Ray Blight co-founded Alcidion in 2000 with Dr. Malcolm Pradhan and served as group CEO and Executive Chairman until the acquisitions of MKM Health and Patientrack in July 2019. In January 2019, Ray stepped down from executive duties and assumed the role of Non-Executive Chairman until September 2019.

Rebecca Wilson, Chair of Alcidion said, “On behalf of the Board, I’d like to thank Ray for his contribution to the Company in his multiple capacities; as the founder of Alcidion, as CEO, Executive Chair and NED of the Board. His deep history with Alcidion and knowledge of the health innovation industry has provided significant value over the last two decades.”

“We are well advanced in appointing a replacement Non-Executive Director, with a strong pool of candidates highly engaged and enthused at the prospect of joining the Alcidion Board at this time of significant momentum and strong growth prospects,” said Ms Wilson.

Outgoing Non-Executive Director of Alcidion Ray Blight said, “It has been a privilege to see Alcidion grow over the past two decades, delivering technology that has been at the forefront of healthcare’s transition to digital delivery. The Company is backed by an excellent leadership team, whom I know ensures Alcidion is in the best position to deliver value to the healthcare providers it works with, the patients its technology is used for, and the shareholders invested in the Alcidion journey.”

An Appendix 3Z is attached to this announcement in relation to Ray Blight’s resignation.

ENDS

For further information, please contact:

Evonne Grosso WE Communications +61 450 603 182 investor@alcidion.com

Alcidion Group Limited | Level 10 9 Yarra Street SOUTH YARRA VIC 3141 |+61 3 8060 6177 | www.alcidion.com

==> picture [110 x 29] intentionally omitted <==

About Alcidion Group Limited (ASX:ALC)

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion’s mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 300 hospitals and 60 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2021. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

This announcement is authorised for release by the Board of Directors of Alcidion Group Limited.

Page 2

Appendix 3Z Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity ALCIDION GROUP LIMITED ABN 77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

the director for the purposes of section 205G of the	Corporations Act.
Name of director	Raymond Howard Blight
Date of last notice	18 May 2021
Date that director ceased to be director	30 June 2021

Part 1 – Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

96,028,781 Fully Paid Ordinary Shares

• See chapter 19 for defined terms.

Appendix 3Z Page 1

Appendix 3Z Final Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest Ms Robyn Gaile Morris (Spouse of Mr Raymond Blight)	Number & class of securities 4,643,050 Fully Paid Ordinary Shares

Part 3 – Director’s interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

• See chapter 19 for defined terms.

Appendix 3Z Page 2